We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Hvivo Plc (HVO) Ord 0.1p

Sell:27.80p Buy:28.10p 0 Change: 0.15p (0.54%)
FTSE AIM 100:0.54%
Market closed Prices as at close on 2 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:27.80p
Buy:28.10p
Change: 0.15p (0.54%)
Market closed Prices as at close on 2 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:27.80p
Buy:28.10p
Change: 0.15p (0.54%)
Market closed Prices as at close on 2 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. It offers additional clinical field trial services, such as patient recruitment and clinical trial site services. It runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

Contact details

Address:
42 New Road
LONDON
E1 2AX
United Kingdom
Telephone:
+44 (028) 90737900
Website:
https://hvivo.com/

Important dates

Future events
Final dividend payment date 20 May 2024 20/05/24
AGM 13 May 2024 13/05/24
Past events
Final ex-dividend date 18 April 2024 18/04/24
Annual report 15 April 2024 15/04/24
Final results 09 April 2024 09/04/24
Trading Announcement 30 January 2024 30/01/24
Interim results 12 September 2023 12/09/23
Trading Announcement 26 July 2023 26/07/23
Special dividend payment date 09 June 2023 09/06/23
AGM 23 May 2023 23/05/23
Special ex-dividend date 04 May 2023 04/05/23

General stock information

EPIC:
HVO
ISIN:
GB00B9275X97
Market cap:
£190.16 million
Shares in issue:
680.37 million
Sector:
Health Care Equipment & Services
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Yamin Mohammed Khan
    Chief Executive Officer, Executive Director
  • Stephen Pinkerton
    Chief Financial Officer, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.